In line / mixed
Life Sciences was strong, but bioprocessing grew roughly 2.5% versus a substantially higher Street bar after more than $100 million of resin orders moved out.
DHRHealth CareLife Sciences Tools & Services
Danaher
The headline beat was overwhelmed by a bioprocessing miss and a guidance cut in the segment investors trusted most.
ResultIn line / mixedGuidanceLoweredEnvironmentworsening
Latest eventQ2 202621 Jul 2026Open full analysis
Latest quarter
The investment read-through
Lowered
Danaher cut the annual bioprocessing growth expectation from high-single digits to mid-single digits and gave a softer Q3 bridge, despite lifting EPS for portfolio actions.
Deceleration
Danaher cut the annual bioprocessing growth expectation from high-single digits to mid-single digits and gave a softer Q3 bridge, despite lifting EPS for portfolio actions.
Qualitative
The shares sold off sharply because a presumed clean recovery signal became a timing and credibility problem.
Latest narrative
What the market is now debating
The market moved from trusting orders to demanding visible shipment conversion and recapture.
Market environment deltaEnvironmentworsening
The headline beat was overwhelmed by a bioprocessing miss and a guidance cut in the segment investors trusted most.
- Demand
- Underlying orders still grew at a double-digit rate, but reported consumables demand did not convert on schedule.
- Supply
- The company described the shortfall as customer shipment timing rather than capacity or share loss; recovery may extend into 2027.
- Competition
- Danaher's resin share makes a sudden broad share loss unlikely, but investors now require proof rather than inference.
Industry-specific KPIs
What this company should be judged on
Core revenue growthBioprocessing ordersBook-to-billChina growthOperating margin
Latest KPI read-through
Danaher cut the annual bioprocessing growth expectation from high-single digits to mid-single digits and gave a softer Q3 bridge, despite lifting EPS for portfolio actions.
[AS-ME-064]Eight-event history
Guidance and narrative timeline
8
21 Jul 2026
Q2 2026
GuidanceLoweredEnvironmentworsening
The headline beat was overwhelmed by a bioprocessing miss and a guidance cut in the segment investors trusted most.
GuidanceDanaher cut the annual bioprocessing growth expectation from high-single digits to mid-single digits and gave a softer Q3 bridge, despite lifting EPS for portfolio actions.NarrativeThe market moved from trusting orders to demanding visible shipment conversion and recapture.
Q2 2026Full analysis→
7
21 Apr 2026
Q1 2026
GuidanceRaisedEnvironmentimproving
A beat-and-raise strengthened the recovery case, but the flow-through was incomplete and respiratory assumptions became less secure.
GuidanceDanaher raised annual earnings but retained much of the operating cushion, while a softer respiratory view limited the revenue benefit.NarrativeThe narrative became an order-to-revenue conversion story rather than a question of order recovery.
Q1 2026Full analysis→
6
28 Jan 2026
Q4 / FY2025
GuidanceMixed / newly framedEnvironmentmixed
A largely preannounced quarter and a prudent 2026 framework offered no incremental catalyst to a crowded position.
GuidanceDanaher initiated 3–6% core growth and $8.35–$8.50 adjusted EPS for 2026, using a conservative floor but no operating upside versus the market's working model.NarrativeThe debate narrowed to the durability and timing of bioprocessing order conversion.
Q4 / FY2025Full analysis→
5
21 Oct 2025
Q3 2025
GuidanceMaintainedEnvironmentimproving
Management removed a major 2026 overhang by framing a credible earnings algorithm on modest core growth.
GuidanceThe 2025 outlook was maintained and management outlined roughly double-digit 2026 earnings growth on about 3% core revenue growth.NarrativeThe market shifted from downside avoidance to underwriting a repeatable earnings algorithm.
Q3 2025Full analysis→
4
22 Jul 2025
Q2 2025
GuidanceMaintainedEnvironmentimproving
The quarter cleared the three largest fears: bioprocessing growth, China procurement pressure and margin conversion.
GuidanceFull-year core growth and earnings were effectively maintained, with the mix supporting the existing second-half bridge.NarrativeThe narrative improved from stabilization to a plausible revenue recovery, but remained dependent on equipment conversion.
Q2 2025Full analysis→
3
22 Apr 2025
Q1 2025
GuidanceLoweredEnvironmentimproving
A clean beat against a de-risked bar confirmed bioprocessing stabilization and protected the earnings floor.
GuidanceThe annual core-growth framework stayed intact and management initiated an EPS range that reduced downside risk despite tariffs and China uncertainty.NarrativeThe market moved from broad downside protection to testing the breadth of the bioprocessing recovery.
Q1 2025Full analysis→
2
29 Jan 2025
Q4 / FY2024
GuidanceMixed / newly framedEnvironmentmixed
A better fourth quarter closed a down year, but the initial 2025 plan embedded a soft first quarter and only modest full-year recovery.
GuidanceDanaher guided to roughly 3% 2025 core growth after a low-single-digit Q1 decline, leaving the recovery weighted to later quarters.NarrativeThe narrative reset to a measured 2025 recovery supported by cash and a firmer bioprocessing order book.
Q4 / FY2024Full analysis→
1
22 Oct 2024
Q3 2024
GuidanceMaintainedEnvironmentworsening
The beat was discounted because its mix pulled demand forward and the unchanged annual plan implied a weak finish.
GuidanceThe maintained 2024 framework mechanically required low-single-digit core decline in Q4, while management described the 2025 recovery as gradual.NarrativeThe debate moved from whether recovery had begun to how slowly orders would become revenue.
Q3 2024Full analysis→